Onco-Summaries: Daily Oncology Updates at a Glance

22/06/2025

The Phase 3 STELLAR-303 trial of zanzalintinib + atezolizumab achieved significant OS benefit in metastatic colorectal cancer (Ref)

• Per topline results from the Phase 3 STELLAR-303/NCT05425940 pivotal trial, Exelixis' zanzalintinib (third-generation oral tyrosine kinase inhibitor) + Roche's atezolizumab (aPD-L1) demonstrated a statistically significant improvement in OS vs regorafenib in previously treated, non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC)

  
  

  • These findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of OS in the ITT population of all randomized patients, regardless of the presence of liver metastases.

  
  

  • The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM).

  
  

  • The safety profiles of zanzalintinib + atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified.

  
  

  • Exelixis will be discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.